Clinical trial • Phase III • Infectious Disease
MK-4646 for HIV infection
Phase III trial of MK-4646 for HIV infection. 14 participants.
Overview
- Trial Therapeutic Area
- Infectious Disease
- Trial Disease
- HIV infection
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 04-04-2025
- First CTIS Authorization Date
- 25-07-2025
Trial design
Phase III trial across 1 site in Romania.
- Target Sample Size
- 14
Eligibility
Recruits 14 Vulnerable population selected; no further details on consent or assent handling provided in source..
- Vulnerable Population
- Vulnerable population selected; no further details on consent or assent handling provided in source.
Recruitment
- Planned Sample Size
- 14
- Recruitment Window Months
- 6
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 14
Romania
- Earliest CTIS Part Ii Submission Date
- 14-04-2025
- Latest Decision Or Authorization Date
- 25-07-2025
- Processing Time Days
- 102
- Number Of Sites
- 1
- Number Of Participants
- 14
Sites
- Site Name
- Institutul National De Boli Infectioase Prof.Dr.Matei Bals
- Department Name
- Institutul National De Boli Infectioase Prof.Dr.Matei Bals ‘Phase I Unit: Pavilion 1, Wards 2,3,4'
- Contact Person Name
- Anca Streinu-Cercel
- Contact Person Email
- anca.streinucercel@gmail.com
- Number Of Participants
- 14
Sponsor
Primary sponsor
- Full Name
- Merck Sharp & Dohme LLC
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- MK-4646
Related trials
Other published trials that may interest you.